JIANGSU RECBIO TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.13 CNY | 0.00% |
|
-1.72% | -15.93% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.451
CNY
Average target price
13.79
CNY
Spread / Average Target
+63.15%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.93% | 559M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 2179 Stock
- News Jiangsu Recbio Technology Co., Ltd.
- China Approves Recbio's Clinical Trial Application for Shingles Vaccine
